Hepatotoxicity induced by cyproterone acetate: A report of three cases

World Journal of Gastroenterology

Volumn 12, Issue 46, 2006, Pages 7551-7555

  Savidou, Ioanna ^a   Deutsch, Melanie ^a   Soultati, Aspasia S ^a   Koudouras, Dimitrios ^a   Kafiri, Georgia ^b   Dourakis, Spyridon P ^a,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b GR 546 42 T   (Greece)

^c NONE   (Greece)

Author keywords

Cyproterone acetate; Drug induced hepatotoxicity; Hepatomitogen action; Idiosyncratic drug reaction; Prostate cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYPROTERONE ACETATE;

AGED; ALCOHOL CONSUMPTION; ASCITES; BRAIN DISEASE; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DEATH; DISEASE SEVERITY; DRUG WITHDRAWAL; FECES ANALYSIS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER PARENCHYMA; LIVER TOXICITY; MALE; PROSTATE CANCER; REVIEW; SEPSIS; URINE COLOR; VIRUS HEPATITIS;

EID: 33845877140     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i46.7551     Document Type: Review

References (36)

1. Levesque H, Trivalle C, Manchon ND, Vinel JP, Moore N, Hemet J, Courtois H, Bercoff E, Bourreille J. Fulminant hepatitis due to cyproterone acetate. Lancet 1989; 1: 215-216
2. Murphy BJ, Collins BJ. Severe hepatitis and liver failure induced by cyproterone acetate. Aust N Z J Med 1996; 26: 724
3. Kacar S, Akdogan M, Kosar Y, Parlak E, Sasmaz N, Oguz P, Aydog G. Estrogen and cyproterone acetate combination-induced autoimmune hepatitis. J Clin Gastroenterol 2002; 35: 98-100
4. Drakos PE, Gez E, Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer 1992; 28A: 1931-1932
5. Roila F, Crino L, Carloni G, Natalini G. Cyproterone acetate: hepatotoxicity and prostatic cancer treatment. Ann Oncol 1993; 4: 701
6. Blake JC, Sawyerr AM, Dooley JS, Scheuer PJ, McIntyre N. Severe hepatitis caused by cyproterone acetate. Gut 1990; 31: 556-557
7. Meijers WH, Willemse PH, Sleijfer DT, Mulder NH, Grond J. Hepatocellular damage by cyproterone acetate. Eur J Cancer Clin Oncol 1986; 22: 1121-1122
8. Heinemann LA, Will-Shahab L, van Kesteren P, Gooren LJ. Safety of cyproterone acetate: report of active surveillance. Pharma coepidemiol Drug Saf 1997; 6: 169-178
9. Manolakopoulos S, Bethanis S, Armonis A, Economou M, Avgerinos A, Tzourmakliotis D. Toxic hepatitis after sequential administration of flutamide and cyproterone acetate. Dig Dis Sci 2004; 49: 462-465
10. Giordano N, Nardi P, Santacroce C, Geraci S, Gennari C. Acute hepatitis induced by cyproterone acetate. Ann Pharmacother 2001; 35: 1053-1055
11. Parys BT, Hamid S, Thomson RG. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991; 67: 312-313
12. Castellani P, Bernardini D, Renou C, Zamora C, Portal I, Gauthier A, Botta-Fridlund D. Fatal sub-fulminant hepatitis caused by cyproterone acetate. A new case. Gastroenterol Clin Biol 1996; 20: 915-916
13. Friedman G, Lamoureux E, Sherker AH. Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci 1999; 44: 1362-1363
14. Hirsch D, Kovatz S, Bernheim J, Shenkman L. Fatal fulminant hepatitis from cyproterone acetate. Isr J Med Sci 1994; 30: 238-240
15. Lombardi A, Ferrazza P, Castaldi F, Covotta L, Tesoriere A, Urbano V, Midiri G. Acute hepatic necrosis in a patient treated with cyproterone acetate. G Chir 1998; 19: 161-163
16. Bressollette L, Dubois A, Carlhant D, Morand C, Mottier D, Riche C. Fatal hepatitis caused by cyproterone acetate. Therapie 1994; 49: 153
17. Antoni M, Bourliere M, Toullec J, Maillot A, Botta-Fridlund D, Gauthier A. Fatal subfulminant hepatitis caused by cyproterone acetate. Gastroenterol Clin Biol 1991; 15: 772-773
18. Garty BZ, Dinari G, Gellvan A, Kauli R. Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate. Eur J Pediatr 1999; 158: 367-370
19. Oberhammer F, Nagy P, Tiefenbacher R, Froschl G, Bouzahzah B, Thorgeirsson SS, Carr B. The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation. Hepatology 1996; 23: 329-237
20. Brambilla G, Martelli A. Are some progestins genotoxic liver carcinogens? Mutat Res 2002; 512: 155-163
21. Kasper, P. Cyproterone acetate: a genotoxic carcinogen? Pharmacol Toxicol 2001; 88: 223-231
22. Manfredi S, Lenfant L, Gresset AC, Bonnotte B, Lorcerie B, Chauffert B. Hepatocellular carcinoma in a healthy liver possibly due to long-term use of cyproterone acetate. Presse Med 2000; 29: 1983
23. Watanabe S, Cui Y, Tanae A, Tanaka T, Fujimoto M, Matsuo Y, Tachibana K, Yamasaki S. Follow-up study of children with precocious puberty treated with cyproterone acetate. Ad hoc Committee for CPA. J Epidemiol 1997; 7: 173-178
24. Ohri SK, Gaer JA, Keane PF. Hepatocellular carcinoma and treatment with cyproterone acetate. Br J Urol 1991; 67: 213-221
25. Kattan J, Spatz A, Culine S, Terrier-Lacombe MJ, Elias D, Droz JP. Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am J Clin Oncol 1994; 17: 390-392
26. Watanabe S, Yamasaki S, Tanae A, Hibi I, Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc Committee on Androcur Users. Lancet 1994; 344: 1567-1568
27. Rudiger T, Beckmann J, Queisser W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol. Lancet 1995; 345: 452-453
28. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485
29. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38 Suppl 2: S44-S48
30. Fasciati R, Maier P. EGF- and CPA-induced mitogenic stimuli are differentially down-regulated by TGF-beta1 in cultured rat hepatocytes. Carcinogenesis 1997; 18: 911-917
31. Low-Baselli A, Hufnagl K, Parzefall W, Schulte-Hermann R, Grasl-Kraupp B. Initiated rat hepatocytes in primary culture: a novel tool to study alterations in growth control during the first stage of carcinogenesis. Carcinogenesis 2000; 21: 79-86
32. Oberhammer FA, Qin HM. Effect of three tumour promoters on the stability of hepatocyte cultures and apoptosis after transforming growth factor-beta 1. Carcinogenesis 1995; 16: 1363-1371
33. Hinkel A, Berges RR, Pannek J, Schulze H, Senge T. Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patients. Eur Urol 1996; 30: 464-70
34. Lin AD, Chen KK, Lin AT, Chang YH, Wu HH, Kuo JY, Huang WJ, Hsu YS, Chung HJ, Chang LS. Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer. J Chin Med Assoc 2003; 66: 735-740
35. Pu YS, Liu CM, Kao JH, Chen J, Lai MK. Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. Eur Urol 1999; 36: 293-297
36. Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004; 73: 289-295